Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.73
+0.34 (0.16%)
AAPL  263.75
-0.97 (-0.37%)
AMD  190.95
-7.67 (-3.86%)
BAC  49.97
+0.16 (0.32%)
GOOG  303.56
-2.80 (-0.91%)
META  655.08
+1.52 (0.23%)
MSFT  403.93
+5.38 (1.35%)
NVDA  180.05
-2.43 (-1.33%)
ORCL  149.01
-0.24 (-0.16%)
TSLA  392.43
-10.89 (-2.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.